Collagenase clostridium histolyticum injection versus limited fasciectomy for the treatment of Dupuytren's disease: a systematic review and meta-analysis of comparative studies
- PMID: 37665353
- DOI: 10.1007/s00402-023-05004-8
Collagenase clostridium histolyticum injection versus limited fasciectomy for the treatment of Dupuytren's disease: a systematic review and meta-analysis of comparative studies
Abstract
Introduction: The aim of the present study is to systematically review the literature on well-selected comparative studies for meta-analysis on outcome differences between collagenase clostridium histolyticum (CCH) injection and limited fasciectomy (LF) for Dupuytren's disease.
Materials and methods: PubMed/Medline, Embase, and the Cochrane Library were searched for comparative studies assessing differences in outcomes of CCH and LF. Effect estimates were pooled across studies using random effects models and presented as weighted mean difference (MD) and odds ratio (OR) with corresponding 95% confidence interval (CI).
Results: A total of 11 studies encompassing 1'051 patients was included (619 patients in the CCH and 432 in the LF group). The residual contracture at a minimal average follow-up of three months was higher in the CCH group than in the LF group (27.8 vs. 16.2°, MD 11.6°, 95% CI [8.7, 14.5°], p < 0.001). The recurrence rate was significantly higher in the CCH group (25.8 vs. 9.3%, OR 5.2, 95% CI [1.5, 18.8], p = 0.01) while the rate of severe complications was significantly higher in the LF group (0.3 vs. 7.3%, OR 0.12, 95% CI [0.03, 0.42], p = 0.001).
Conclusions: Evidence of the present study confirms that CCH injection has a higher rate of disease recurrence whereas LF carries a higher risk for severe complications. It's imperative that the trade-off between these aspects is considered, keeping in mind that CCH injections may be repeated in case of disease recurrence without increasing procedure related risks, especially in complex cases.
Keywords: Collagenase injection; Dupuytren’s disease; Limited fasciectomy; Meta-analysis.
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Similar articles
-
Dupuytren's Contracture Recurrence and Treatment Following Collagenase Clostridium Histolyticum Injection: A Longitudinal Assessment in a Veteran Population.Mil Med. 2023 Aug 29;188(9-10):e2975-e2981. doi: 10.1093/milmed/usad075. Mil Med. 2023. PMID: 36928340
-
The efficacies and limitations of fasciectomy and collagenase clostridium histolyticum in Dupuytren's contracture management: A meta-analysis.J Orthop Surg (Hong Kong). 2020 Jan-Apr;28(2):2309499020921747. doi: 10.1177/2309499020921747. J Orthop Surg (Hong Kong). 2020. PMID: 32484064 Review.
-
Range of motion, postoperative rehabilitation and patient satisfaction in MCP and PIP joints affected by Dupuytren Tubiana stage 1-3: collagenase enzymatic fasciotomy or limited fasciectomy? A clinical study in 52 patients.Arch Orthop Trauma Surg. 2018 Nov;138(11):1623-1631. doi: 10.1007/s00402-018-3034-6. Epub 2018 Sep 26. Arch Orthop Trauma Surg. 2018. PMID: 30259125
-
Collagenase clostridium histolyticum for the treatment of Dupuytren's contracture: systematic review and economic evaluation.Health Technol Assess. 2015 Oct;19(90):1-202. doi: 10.3310/hta19900. Health Technol Assess. 2015. PMID: 26524616 Free PMC article. Review.
-
Safety and tolerability of collagenase Clostridium histolyticum and fasciectomy for Dupuytren's contracture.J Hand Surg Eur Vol. 2015 Feb;40(2):141-9. doi: 10.1177/1753193414528843. Epub 2014 Apr 2. J Hand Surg Eur Vol. 2015. PMID: 24698851 Free PMC article. Review.
Cited by
-
A conserved strategy to attack collagen: The activator domain in bacterial collagenases unwinds triple-helical collagen.Proc Natl Acad Sci U S A. 2024 Apr 16;121(16):e2321002121. doi: 10.1073/pnas.2321002121. Epub 2024 Apr 9. Proc Natl Acad Sci U S A. 2024. PMID: 38593072 Free PMC article.
References
-
- Huang C, Ogawa R (2012) Fibroproliferative disorders and their mechanobiology. Connect Tissue Res 53:187–196. https://doi.org/10.3109/03008207.2011.642035 - DOI - PubMed
-
- Hu FZ, Nystrom A, Ahmed A, Palmquist M, Dopico R, Mossberg I et al (2005) Mapping of an autosomal dominant gene for Dupuytren’s contracture to chromosome 16q in a Swedish family. Clin Genet 68:424–429. https://doi.org/10.1111/J.1399-0004.2005.00504.X - DOI - PubMed
-
- Ling R (1963) The genetic factor in Dupuytren’s disease. J Bone Jt Surg 45:709–718 - DOI
-
- Broekstra DC, Groen H, Molenkamp S, Werker PMN, van den Heuvel ER (2018) A Systematic review and meta-analysis on the strength and consistency of the associations between dupuytren disease and diabetes mellitus, liver disease, and epilepsy. Plast Reconstr Surg 141:367e–379e. https://doi.org/10.1097/PRS.0000000000004120 - DOI - PubMed
-
- Lanting R, Broekstra DC, Werker PMN, Van Den Heuvel ER (2014) A systematic review and meta-analysis on the prevalence of Dupuytren disease in the general population of western countries. Plast Reconstr Surg 133:593–603. https://doi.org/10.1097/01.PRS.0000438455.37604.0F - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources